22nd Century Group Inc's Stock Drops 12.26%, but Shows Recent Recovery

Business by 2FIRSTS.ai
Dec.06.2023
22nd Century Group Inc's Stock Drops 12.26%, but Shows Recent Recovery
22nd Century Group Inc's stock price fell 12.26% from its previous closing price of 0.26, despite a 10.19% increase in the past five trading days.

According to a report by Zacks Investment Research, the stock price of 22nd Century Group Inc (NASDAQ: XXII) has dropped by 12.26 percentage points, closing at 0.26 below its previous closing price.

 

Despite this, the company's stock price has risen by 10.19% over the past five trading days. The VLN tobacco products of 22nd Century Group have been certified by the US FDA as reduced-risk tobacco products for the first time.

 

The question of whether the stock of 22nd Century Group Inc. (NASDAQ: XXII) is worth investing in has received mixed market reactions. The company's stock has experienced a 10.19% increase over the past week, but has seen declines of 50.64% and 84.90% over the past 30 days and 90 days respectively.

 

The performance of 22nd Century Group Inc. (NASDAQ: XXII) in recent times has been unable to surpass its 52-week low, resulting in the company sustaining a loss of -98.77% over a period of time. However, in the past five trading days, the stock has shown some recovery, reaching a gain of +10.19%. Nonetheless, it has still dropped by 98.43% compared to the 200-day moving average of 0.3131 USD.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Altria Director George Muñoz to Retire After 2026 Shareholder Meeting;
Altria Director George Muñoz to Retire After 2026 Shareholder Meeting;
Altria director George Muñoz plans to retire post-2026 annual meeting, not seeking re-election. Annual meeting expected on May 14.
Oct.15 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Yekaterinburg shuts down illegal e-cigarette oil factory; Russia plans to ban e-cigarette sales
Yekaterinburg shuts down illegal e-cigarette oil factory; Russia plans to ban e-cigarette sales
An illegal e-cigarette oil factory was shut down in Yekaterinburg, Russia. The illegal e-cigarette oil was produced under unsanitary conditions, with falsified addresses and production dates on product labels. Some of the employees were hearing-impaired. The Russian government plans a complete ban on e-cigarette sales, which has received support from the president.
Sep.30 by 2FIRSTS.ai
Russia’s Environmental Operator Proposes Raising Eco Levies on E-Cigarette Manufacturers: “Fee-Driven Remediation” for Hazardous Waste
Russia’s Environmental Operator Proposes Raising Eco Levies on E-Cigarette Manufacturers: “Fee-Driven Remediation” for Hazardous Waste
Because disposable e-cigarettes (with onboard batteries) are difficult to recycle, costly to process, and pose environmental risks, the Russian Environmental Operator (REO) has proposed increasing the environmental (eco) levy on manufacturers and importers of e-cigarettes. REO says the proceeds would fund compliant disposal firms and push improvements in product design and take-back capacity. The funds collected would be directed to support licensed processors, and REO is currently working with
Sep.25 by 2FIRSTS.ai
Thai police arrested a 28-year-old woman and seized e-cigarettes worth approximately $2,508
Thai police arrested a 28-year-old woman and seized e-cigarettes worth approximately $2,508
A 28-year-old Thai woman was arrested in a luxury apartment on suspicion of illegally selling e-cigarettes. Police seized 150 e-cigarettes with a total value of about 80,000 baht (about US$2,508).
Sep.18 by 2FIRSTS.ai
InterTabac 2025 Insights|RELX Unveils “Vaporless” Showcase Cabinet Featuring Nicotine Airpouch and Prototype Vaporless Device
InterTabac 2025 Insights|RELX Unveils “Vaporless” Showcase Cabinet Featuring Nicotine Airpouch and Prototype Vaporless Device
At InterTabac 2025, RELX’s oral-nicotine showcase featured leaf-shaped Nicotine Airpouch products under the WAKA, RELX, and DOSH brands, alongside a prototype “vaporless oral product.” The device produces no visible aerosol upon exhalation during light puffs and is currently for exhibition only, with no confirmed launch timeline. RELX also displayed a nose-inhaled e-cigarette that differs from conventional mouth-inhaled vaping by requiring nasal inhalation.
Sep.20 by 2FIRSTS.ai